A Study in Greece Observing How Patients with Stomach and Esophageal Cancer are Diagnosed and Treated in Everyday Medical Practice - GRACE
Study identifier:D133HR00065
ClinicalTrials.gov identifier:NCT07800754
EudraCT identifier:N/A
CTIS identifier:N/A
Will Be Recruiting
Official Title
Epidemiological Characteristics And Management Strategies Of Gastric/Gastrophaegal Junction Cancer Patients In Routine Clinical Practice: A Greek Multicenter Observational Study (The GRACE Study)
Medical condition
gastric cancer
Phase
-
Healthy volunteers
no
Study drug
-
Sex
All
Estimated Enrollment
300
Study type
Observational
Age
18 Years - 130 Years
Date
Study Start Date: 30 Sept 2026
Estimated Primary Completion Date: 31 Dec 2027
Estimated Study Completion Date: 31 Dec 2027
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jul 2026 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
No locations available
| Arms | Assigned Interventions |
|---|---|
| Patients with Stage II-IVB Gastric/GEJ Adenocarcinoma Adult patients with histologically confirmed, stage II to IVB gastric/GEJ adenocarcinoma will be enrolled from 10-15 oncology clinics of large public and private hospitals, covering diverse geographic areas, in Greece. Eligible patients will have been diagnosed between June 1st, 2025 and the end of the recruitment period (Q3 2027). The study includes both retrospective and prospective components. | - |
